«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年01期

页码:

1-6

栏目:

基础医学

出版日期:

2018-01-20

文章信息/Info

Title:

Effect of PRRX1 expression on VM formation and prognosis in ovarian cancer

文章编号:

1006-8147(2018)01-0001-06

作者:

范 丹¹; 宋文静1; 2; 张艳辉3; 戚 红1; 古 强1; 2; 董学易1; 2; 刘 芳1; 2; 赵秀兰1; 2; 孙保存1; 2; 3

（1.天津医科大学病理学教研室，天津 300070；2.天津医科大学总医院病理科，天津 300052；3.天津医科大学肿瘤医院病理科，天津 300060）

Author(s):

FAN Dan¹;  SONG Wen-jing¹; 2;  ZHANG Yan-hui³; QI Hong¹;  GU Qiang¹; 2;  DONG Xue-yi¹; 2;  LIU Fang¹; 2;  ZHAO Xiu-lan¹; 2; SUN Bao-cun¹; 2; 3

（1. Department of Pathology, Tianjin Medical University, Tianjin 300070, China; 2.Department of Pathology, General Hospital，Tianjin Medical University, Tianjin 300052, China; 3. Department of Pathology, Cancer Hospital，Tianjin Medical University, Tianjin 300060, China）

关键词:

卵巢癌; 配对相关同源框1; 血管生成拟态; β-catenin; Wnt5a

Keywords:

ovarian cancer;  paired related homeobox 1;  vasculogenic mimicry;  β-catenin;  Wnt5a

分类号:

R737.31

DOI:

-

文献标志码:

A

摘要:

目的:检测配对相关同源框1(PRRX1)及其通路分子在卵巢癌中表达情况以及其与血管生成拟态(VM)的关系，推测PRRX1对卵巢癌患者预后的影响。方法:采用免疫组化法检测62例卵巢癌中 PRRX1、Wnt5a、β-catenin的表达情况，采用CD31/PAS双染法检测卵巢癌中VM的情况。采用χ²检验和Pearson相关分析来分析PRRX1与VM形成和临床病理资料之间的关系以及PRRX1与Wnt5a、β-catenin的关系。采用Kaplan-Meier法评估 PRRX1对卵巢癌患者生存预后的影响。结果:PRRX1表达对卵巢癌患者的FIGO分期、转移及VM形成有影响且具有统计学意义(P <0.05)，而对患者的年龄、肿瘤大小、组织学类型、肿瘤分化程度的影响无明显的统计学差异(P >0.05)。PRRX1表达与β-catenin的核表达有关，与Wnt5a、β-catenin的浆表达无关。PRRX1阳性表达和有VM形成的患者生存时间比PRRX1阴性表达或无VM形成的患者短(P <0.05)且预后差；PRRX1阳性表达和β-catenin核阳性表达的患者生存时间短于PRRX1阴性表达或β-catenin核阴性表达的患者(P <0.05)；而PRRX1阳性表达与Wnt5a阳性表达、β-catenin的浆阳性表达的患者生存时间与PRRX1阴性表达或Wnt5a阴性表达、β-catenin的浆阴性表达的患者生存时间相比，差别无意义(P >0.05)。结论:PRRX1通过 Wnt/β-catenin信号通路调节VM形成从而影响卵巢癌患者预后，PRRX1可作为卵巢癌诊断和预后预测的指标。

Abstract:

Objective: To investigate the paired related homeobox 1 (PRRX1) and its pathway molecules expression in ovarian cancer and its relationship with the vasculogenic mimicry(VM) formation, so as to explore PRRX1 effect on metastasis and prognosis in ovarian cancer. Methods: The expressions of PRRX1,Wnt5a,β-catenin as well as VM in ovarian cancer samples from 62 cases were examined by immunohistochemical and CD31/periodic acid-Schiff double staining. And the relationships between PRRX1 and VM formation, Wnt5a,β-catenin were assessed byχ² and pearson tests. The prognostic values of PRRX1 were measured by Kaplan-Meier survival analysis. Results: PRRX1 expression was associated with FIGO stage, metastasis and VM formation(P <0.05).No significant correlations were found between PRRX1 and age, tumor size, histological type, degree of differentiation of the tumor(P >0.05). PRRX1 overexpression was found to have the relationship with β-catenin nuclear expression but showed no relationship with Wnt5a and β-catenin cytoplasm expression. Both PRRX1 expression and VM formation were correlated with ovarian cancer metastasis and prognosis. Kaplan-Meier survival analysis showed that patients with PRRX1 expression and VM formation had shorter survival than PRRX1^-or VM^- patients, respectively. And poor prognosiswas observed; PRRX1 expression and β-catenin nuclear expression had shorter survival than PRRX1^-or β-catenin nuclear negative expression (P <0.05),where this relationship showed no significance between PRRX1 and Wnt5a,β-catenincytoplasm expression (P >0.05).Conclusion: PRRX1 could regulate VM formation in ovarian cancer through the activation of Wnt/β-catenin signaling, indicating poor prognosis, so PRRX1 might be a candidate marker for the diagnosis and prognosis predictor of ovarian cancer.

参考文献/References:

[1]Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003[J]. CA Cancer J Clin, 2003,53(1):5 [2]Eisenkop S M, Friedman R L, Spirtos N M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma[J]. Cancer, 2000,88(1):144
[3]Lv Z D,Yang Z C, Liu X P, et al. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer[J]. J Cell Mol Med, 2016,20(9):1640
[4]Lv Z D, Kong B, Liu X P, et al. miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer[J]. J Cell Mol Med, 2016,20(5):864
[5]Guo J, Fu Z, Wei J, et al. PRRX1 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer[J]. Med Oncol, 2015,32(1):393
[6]Takahashi Y, Sawada G, Kurashige J, et al. Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer[J]. Br J Cancer, 2013,109(2):307
[7]Zhao H, Gu X M. Study on vasculogenic mimicry in malignant esophageal stromal tumors[J].World J Gastroenterol , 2008,14(15):2430
[8]Folkman J. Role of angiogenesis in tumor growth and metastasis[J]. Semin Oncol, 2002,29(6, Supplement 16):15
[9]Mihic-Probst D, Ikenberg K, Tinguely M, et al. Tumor cell plasticity and angiogenesis in human melanomas[J]. PLoS One, 2012,7(3):e33571
[10]Fan Y L, Zheng M, Tang Y L, et al. A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review)[J]. Oncol Lett, 2013,6(5):1174
[11]Sun T, Zhao N, Zhao X L, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry[J]. Hepatology, 2010,51(2):545
[12]Liu Z, Sun B, Qi L, et al. Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition[J]. Cancer Sci, 2012,103(4):813
[13]Kern M J, Argao E A, Birkenmeier E H, et al. Genomic organization and chromosome localization of the murine homeobox gene Pmx[J]. Genomics, 1994,19(2):334
[14]Mani S A, Guo W J, Liao M J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008,133(4):704
[15]Oca?a O H, Córcoles R, Fabra A, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1[J]. Cancer Cell, 2012,22(6):709
[16]Regadas I, Matos M R, Monteiro F A, et al. Several cis-regulatory elements control mRNA stability, translation efficiency, and expression pattern of Prrxl1 (paired related homeobox protein-like 1)[J]. J Biol Chem, 2013,288(51):36285
[17]Takimoto A, Mohri H, Kokubu C, et al. Pax1 acts as a negative regulator of chondrocyte maturation[J]. Exp Cell Res, 2013,319(20):3128
[18]Ten Berge D, Brouwer A, Korving J, et al. Prx1 and Prx2 in skeletogenesis: roles in the craniofacial region, inner ear and limbs[J]. Development,1998,125(19):3831
[19]Lu X, Beck G R, Gilbert L C, et al. Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation[J]. J Bone Miner Res, 2011,26(1):209
[20]Martin J F, Bradley A, Olson E N. The paired-like homeo box gene MHox is required for early events of skeletogenesis in multiple lineages[J]. Genes Dev, 1995,9(10):1237
[21]Shimozaki K, Clemenson G D, Gage F H. Paired related homeobox protein 1 is a regulator of stemness in adult neural stem/progenitor cells[J]. J Neurosci, 2013,33(9):406
[22]Ihida-Stansbury K, Mckean D M, Gebb S A, et al. Paired-related homeobox gene Prx1 is required for pulmonary vascular development[J]. Circ Res, 2004,94(11):1507
[23]Reichert M, Takano S, Von Burstin J, et al. The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis[J]. Genes Dev, 2013,27(3):288
[24]Sugiyama M, Hasegawa H, Ito S, et al. Paired related homeobox 1 is associated with the invasive properties of glioblastoma cells[J]. Oncol Rep, 2015,33(3):1123
[25]Wodarz A, Nusse R. Mechanisms of Wnt signaling in development[J]. Annu Rev Cell Dev Biol,1998，14：59:
[26]Lucero O M, Dawson D W, Moon R T, et al. A re-evaluation of the "oncogenic" Nature of Wnt/beta-catenin signaling in melanoma and other cancers[J]. Curr Oncol Rep, 2010,12(5):314
[27]Kim H J, Schleiffarth J R, Jessurun J, et al. Wnt5 signaling in vertebrate pancreas development[J]. BMC Biol, 2005，3:23
[28]Kremenevskaja N, Von Wasielewski R, Rao A S, et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma[J]. Oncogene, 2005,24(13):2144
[29]Kurayoshi M, Oue N, Yamamoto H, et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion[J]. Cancer Res, 2006,66(21):10439
[30]Clevers H, Nusse R. Wnt/β-Catenin signaling and disease[J]. Cell, 2012,149(6):1192
[31]Cselenyi C S, Jernigan K K, Jahinci E, et al. LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3’s phosphorylation of beta-catenin[J]. Proc Natl Acad Sci U S A, 2008,105(23):8032
[32]Arend R C, Londo?o-Joshi A I, Straughn J M, et al. The Wnt/β-catenin pathway in ovarian cancer: a review[J]. Gynecol Oncol, 2013,131(3):772
[33]Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function[J]. J Cell Biochem, 1996,61(4):514
[34]Oyama T, Kanai Y, Ochiai A, et al. A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines[J]. Cancer Res,1994,54(23):6282
[35]Qi L, Song W, Liu Z, et al. Wnt3a promotes the vasculogenic mimicry formation of colon cancer via Wnt/β-Catenin signaling[J]. Int J Mol Sci, 2015,16(8):18564
[36]汤晓颖,庞林宾,宋立文,等. XAV939抑制人肝癌HepG2细胞血管生成拟态的形成[J].基础医学与临床, 2015,35(3):345

相似文献/References:

[1]申彦,张新莹,师宜荃,等.Glut-1、HIF-1α及P53在卵巢癌中的表达及意义[J].天津医科大学学报,2013,19(05):383.
[2]周 闻,杨 臻,刘 民,等.抑癌基因ST7L对卵巢癌细胞增殖、细胞周期和裸鼠移植瘤的影响[J].天津医科大学学报,2016,22(05):373.
　ZHOU Wen,YANG Zhen,LIU Min,et al.Effects of ST7L on cell proliferation, cell cycle in ovarian cancer and tumour xenografts in nude mice[J].Journal of Tianjin Medical University,2016,22(01):373.
[3]徐灵灵,牛秀珑,张宏健,等.IL-17A促进卵巢癌顺铂耐药的体外机制探讨[J].天津医科大学学报,2018,24(03):192.
　XU Ling-ling,NIU Xiu-long,ZHANG Hong-jian,et al.Study on the underlying mechanisms of IL-17A promoting the cisplatin-based resistance of ovarian cancer[J].Journal of Tianjin Medical University,2018,24(01):192.
[4]王雅蕾,王靖怡 综述,齐丽莎 审校.微环境在卵巢癌发生发展中的作用[J].天津医科大学学报,2020,26(03):288.
[5]李岩,牛秀珑,郁春艳,等.IL-17A可以促进卵巢癌的腹腔转移[J].天津医科大学学报,2020,26(06):518.
　LI Yan,NIU Xiu-long,YU Chun-yan,et al.IL-17A promotes intraperitoneal metastasis of ovarian cancer[J].Journal of Tianjin Medical University,2020,26(01):518.
[6]李广宁 综述,曹文枫 审校.女性生殖系统双原发癌的研究进展[J].天津医科大学学报,2021,27(06):655.
[7]沈洋洋,牛秀珑,郁春艳,等.外源性IL-6 通过STAT3 通路促进卵巢癌细胞对顺铂 耐药[J].天津医科大学学报,2022,28(03):266.
　SHEN Yang-yang,NIU Xiu-long,YU Chun-yan,et al.Exogenous IL-6 promotes cisplatin resistance of ovarian cancer through STAT3 pathway[J].Journal of Tianjin Medical University,2022,28(01):266.
[8]郑小燕,郁春艳,刘俊汝,等.IL-17A对卵巢癌进展的影响及机制研究[J].天津医科大学学报,2023,29(02):148.
　ZHENG Xiao-yan,YU Chun-yan,LIU Jun-ru,et al.Effect and mechanism of IL-17A on the progression of ovarian cancer[J].Journal of Tianjin Medical University,2023,29(01):148.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金面上项目基金资助（81572872）

作者简介 范丹（1990-），女，硕士在读，研究方向：肿瘤病理学；通信作者：宋文静，E-mail: songwenjing2004@aliyun.com；赵秀兰，E-mail: xiulanzhao@aliyun.com。

常用功能

更新日期/Last Update: 2018-01-19